Published in World J Gastroenterol on December 28, 2010
Cytokine-induced killer cells promote antitumor immunity. J Transl Med (2013) 1.16
Immunotherapy in gastric cancer. World J Gastroenterol (2014) 0.96
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol (2013) 0.89
Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res (2014) 0.86
Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit (2014) 0.82
Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects. World J Gastroenterol (2015) 0.78
Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chin J Cancer (2015) 0.78
Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy. Int J Clin Exp Med (2015) 0.78
Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol (2015) 0.78
Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. Oncol Lett (2015) 0.76
Effect of cytokine-induced killer cells on immune function in patients with lung cancer. Oncol Lett (2016) 0.75
A Positive Role of Cytokine-Induced Killer Cell Therapy on Gastric Cancer Therapy in a Chinese Population: A Systematic Meta-Analysis. Med Sci Monit (2015) 0.75
Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion. Med Sci Monit (2016) 0.75
Clinical effects of autologous cytokine-induced killer cell-based immunotherapy in the treatment of endometrial cancer: a case report and literature review. Onco Targets Ther (2017) 0.75
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer (1999) 6.11
Recurrence following curative resection for gastric carcinoma. Br J Surg (2000) 4.67
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med (1991) 3.03
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics (1982) 2.74
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 2.65
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 2.02
Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst (1985) 1.78
Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol (2010) 1.67
Evolving chemotherapy for advanced gastric cancer. Oncologist (2005) 1.62
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol (2009) 1.56
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res (2009) 1.38
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol (1996) 1.38
Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res (2006) 1.25
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother (2010) 1.23
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer (2006) 1.21
Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis. Cancer Immunol Immunother (2000) 1.19
Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol (2009) 1.18
Molecular basis of therapeutic approaches to gastric cancer. J Gastroenterol Hepatol (2009) 1.18
Gastric cancer. Crit Rev Oncol Hematol (2005) 1.16
Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol (2008) 1.15
Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother (2009) 1.10
Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science (1993) 1.08
Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol (1996) 1.02
Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol (2005) 1.01
Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev (1997) 0.96
Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol (2007) 0.94
In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res (1989) 0.93
Intraoperative radiation therapy for gastric cancer. World J Surg (1995) 0.93
Gastric cancer. Clin Adv Hematol Oncol (2005) 0.92
Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant (1995) 0.92
Developments in clinical cell therapy. Cytotherapy (2010) 0.91
Adoptive cellular therapy. Semin Oncol (2000) 0.90
Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A (2009) 0.89
Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother (2002) 0.88
Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B (2005) 0.86
Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol (2004) 0.85
[Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Zhonghua Zhong Liu Za Zhi (2004) 0.85
[Clinical study on early use of Chinese medicinal herbs and chemotherapy after operation of gastric cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi (1995) 0.81
Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol (2004) 0.80
[Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor]. Ai Zheng (2002) 0.80
T-lymphocyte subsets in patients with AJCC stage III gastric cancer during postoperative adjuvant chemotherapy. American Joint Committee on Cancer. Scand J Surg (2002) 0.80
[Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals]. Zhong Xi Yi Jie He Za Zhi (1990) 0.78
Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori (1998) 0.77
Cancer therapy by biological response modifiers. Clin Physiol Biochem (1987) 0.76
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology (2005) 5.33
Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol (2006) 3.85
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol (2010) 3.06
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Gamma-secretase gene mutations in familial acne inversa. Science (2010) 2.30
TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell (2008) 2.26
The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA. Proc Natl Acad Sci U S A (2006) 2.12
Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest (2002) 1.96
VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation (2006) 1.86
Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl (2009) 1.86
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 1.75
Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res (2010) 1.73
Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. Proc Natl Acad Sci U S A (2011) 1.61
Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology (2009) 1.58
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Post-genome wide association studies and functional analyses identify association of MPP7 gene variants with site-specific bone mineral density. Hum Mol Genet (2011) 1.53
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
The Th17 immune response is controlled by the Rel-RORγ-RORγ T transcriptional axis. J Exp Med (2011) 1.50
Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol (2006) 1.50
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
Complete assignment of the chromosomes of Gossypium hirsutum L. by translocation and fluorescence in situ hybridization mapping. Theor Appl Genet (2006) 1.48
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res (2007) 1.47
TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One (2012) 1.44
Gene expression profiling of the early pulmonary response to hyperoxia in mice. Am J Respir Cell Mol Biol (2003) 1.41
Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One (2012) 1.40
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res (2006) 1.40
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc Natl Acad Sci U S A (2012) 1.40
ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol (2009) 1.40
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer (2009) 1.37
A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem Int Ed Engl (2009) 1.35
Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol (2007) 1.35
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother (2011) 1.34
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Learning curve of transumbilical single incision laparoscopic cholecystectomy (SILS): a preliminary study of 80 selected patients with benign gallbladder diseases. World J Surg (2011) 1.30
Laparoscopic complete mesocolic excision (CME) with medial access for right-hemi colon cancer: feasibility and technical strategies. Surg Endosc (2012) 1.28
The immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol Rev (2004) 1.27
Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res (2005) 1.26
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther (2010) 1.23
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother (2010) 1.23
Critical roles of Bim in T cell activation and T cell-mediated autoimmune inflammation in mice. J Clin Invest (2009) 1.22
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer (2011) 1.20
Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther (2005) 1.20
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res (2005) 1.19
Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem (2011) 1.17
Graft-union development: a delicate process that involves cell-cell communication between scion and stock for local auxin accumulation. J Exp Bot (2012) 1.16
Production of aqueous colloidal dispersions of carbon nanotubes. J Colloid Interface Sci (2003) 1.16
Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm (2009) 1.16
miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett (2013) 1.16
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther (2010) 1.15
Rapid fabrication of large-area, corrosion-resistant superhydrophobic Mg alloy surfaces. ACS Appl Mater Interfaces (2011) 1.15
Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects. Cancer Biol Ther (2007) 1.15
Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol Cell Biochem (2004) 1.15
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14
Serratia nematodiphila sp. nov., associated symbiotically with the entomopathogenic nematode Heterorhabditidoides chongmingensis (Rhabditida: Rhabditidae). Int J Syst Evol Microbiol (2009) 1.13
Stable aqueous dispersion of ZnO quantum dots with strong blue emission via simple solution route. J Am Chem Soc (2007) 1.13
Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol (2014) 1.12
Systemic polyethylene glycol-modified (PEGylated) superoxide dismutase and catalase mixture attenuates radiation pulmonary fibrosis in the C57/bl6 mouse. Radiother Oncol (2006) 1.11
One-step synthesis of polysubstituted benzene derivatives by multi-component cyclization of alpha-bromoacetate, malononitrile and aromatic aldehydes. Chem Commun (Camb) (2008) 1.10
Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells. J Neurochem (2004) 1.10
Phospholipase Cgamma/diacylglycerol-dependent activation of beta2-chimaerin restricts EGF-induced Rac signaling. EMBO J (2006) 1.09
A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet (2013) 1.08
Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res (2013) 1.07
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med (2011) 1.07
Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol (2003) 1.07
RNA interference-mediated signal transducers and activators of transcription 3 gene silencing inhibits invasion and metastasis of human pancreatic cancer cells. Cancer Sci (2007) 1.07
The in vitro and in vivo anti-tumor effect of layered double hydroxides nanoparticles as delivery for podophyllotoxin. Int J Pharm (2010) 1.07
Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One (2012) 1.07
Estimation of images and nonrigid deformations in gated emission CT. IEEE Trans Med Imaging (2006) 1.07
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res (2007) 1.06
Lipids changes in liver cancer. J Zhejiang Univ Sci B (2007) 1.06
PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization. Blood (2002) 1.06
Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther (2011) 1.06
L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease. J Neurosci (2010) 1.05
Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother (2012) 1.05
DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm (2010) 1.05
Dietary flaxseed enhances antioxidant defenses and is protective in a mouse model of lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol (2007) 1.04
The Chinese herb isolate isorhapontigenin induces apoptosis in human cancer cells by down-regulating overexpression of antiapoptotic protein XIAP. J Biol Chem (2012) 1.04
Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan). J Biol Chem (2010) 1.04
Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World J Gastroenterol (2003) 1.03
Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity. Int Immunopharmacol (2012) 1.02
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol (2012) 1.02
B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med (2012) 1.02
Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One (2011) 1.01
Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials (2009) 1.01
Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett (2011) 1.01
miR-320a suppresses colorectal cancer progression by targeting Rac1. Carcinogenesis (2013) 1.01
A traceless approach for the solid-phase parallel synthesis of trisubstituted oxindoles. J Comb Chem (2007) 1.01
Predicting iron-fortified soy sauce consumption intention: application of the theory of planned behavior and health belief model. J Nutr Educ Behav (2006) 1.01
A small library of DNA-encapsulated supramolecular nanoparticles for targeted gene delivery. Chem Commun (Camb) (2010) 1.00
Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer (2013) 0.99